Alithea Genomics
AG
AL

Alithea Genomics

Agent22Agent Readiness: 22/100. Bottom 25%. Measured by StartupHub.ai. Median 41.

Unlocking industrial-scale RNA-seq for primary drug screening and toxicology.

Website
2021InactiveZurich, Switzerland

About

Alithea Genomics is a biotechnology company focused on revolutionizing drug discovery and toxicology through its proprietary RNA sequencing technology. Their platform enables industrial-scale RNA sequencing, making it more accessible and efficient for primary drug screening and toxicity assessments. This allows for faster identification of potential drug candidates and a more comprehensive understanding of their safety profiles.

Key facts

At-a-glance profile data

Website
alithea-genomics.com
Headquarters
Zurich, Switzerland
Founded
2021
Total funding
$11M (Seed)
Business model
B2B

Funding rounds

Funding rounds raised by Alithea Genomics
DateRoundAmountLead investors
3 Mar 2026Seed$7M-
14 Mar 2024Seed Extension$3M-
24 May 2022Seed$1M-
Add first review

Frequently asked

How much funding has Alithea Genomics raised?

Alithea Genomics has raised a total of $11M in funding. The most recent round on record is Seed.

What is Alithea Genomics's current status?

Alithea Genomics's current operating status is: Inactive.